Results 131 to 140 of about 33,833 (238)

A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex

European Respiratory Journal
Extract We echo the latest calls that have been made to increase the capacity for antimicrobial susceptibility testing (AST) for bedaquiline for the Mycobacterium tuberculosis complex [1, 2].
C. Köser, P. Miotto, N. Ismail, Richard M. Anthony, C. Utpatel, M. Merker, S. Niemann, S. Tahseen, L. Rigouts, Camilla Rodrigues, S. Omar, M. R. Farhat, U. Antonenka, Harald Hoffmann, Daniela M. Cirillo, Thomas Schön   +15 more
semanticscholar   +1 more source

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

Therapeutics and Clinical Risk Management, 2014
Eric Leibert, Mauricio Danckers, William N Rom Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, NY, USA Abstract: Mycobacterium tuberculosis develops spontaneous ...
Leibert E, Danckers M, Rom WN
doaj  

Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Background: Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and leads to serious complications if left untreated. Some strains of Mycobacterium tuberculosis are multi-drug resistant and require treatment with newer drugs ...
Obaid Ur Rehman, Eeshal Fatima, Abraish Ali, Umar Akram, Abdulqadir Nashwan, Faryal Yunus   +5 more
doaj   +1 more source

Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy
Bedaquiline (BDQ) is crucial for the treatment of rifampicin-resistant tuberculosis, yet resistance threatens its effectiveness, mainly linked to mutations in the mmpR5 (Rv0678) gene.
J. Snobre, C. Meehan, W. Mulders, L. Rigouts, R. Buyl, B. C. de Jong, A. van Rie, O. Tzfadia   +7 more
semanticscholar   +1 more source

MmpR5 protein truncation and bedaquiline resistance in Mycobacterium tuberculosis isolates from South Africa: a genomic analysis.

The Lancet Microbe
BACKGROUND The antibiotic bedaquiline is a key component of new WHO regimens for drug-resistant tuberculosis; however, predicting bedaquiline resistance from bacterial genotypes remains challenging.
Leah W. Roberts, Kerri M. Malone, M. Hunt, L. Joseph, Penelope Wintringer, Jeff Knaggs, Derrick W. Crook, M. R. Farhat, Zam Iqbal, S. Omar   +9 more
semanticscholar   +1 more source

Mycobacterium tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia

International Journal of Microbiology
Tuberculosis (TB) is caused by Mycobacterium tuberculosis infection. Indonesia is ranked second in the world for TB cases. New anti‐TB drugs from groups A and B, such as bedaquiline, clofazimine, and linezolid, have been shown to be effective in curing ...
Andriansjah Rukmana, Cynthia Gozali, Linda Erlina   +2 more
semanticscholar   +1 more source

Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings [PDF]

, 2016
In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few repurposed compounds to treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB), clinicians are facing increasing problems in ...
Centis, R, D'Ambrosio, L, Fuentes, Z, Migliori, GB, Sotgiu, G, Tiberi, S, Zumla, A   +6 more
core  

Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis

Therapeutic Drug Monitoring
Background: Pharmacokinetic studies of bedaquiline and delamanid in patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB) will help in the optimization of these drugs for both culture conversion and adverse events. Methods: A prospective
Anuj Bhatnagar, A. Hemanthkumar, Mariappan Muthu Vijayalakshmi, V. Vohra, C. Padmapriyadarsini, P. M. Ramesh, Gaurav Taneja, Vijay Chavan, B. Jeyadeepa, N. K. Bhui, Rajesh Solanki   +10 more
semanticscholar   +1 more source

QT Prolongation Associated with Administration of Bedaquiline, a Novel Anti-Tuberculosis Drug.

Cardiology in Review
Bedaquiline is a diarylquinoline compound that has recently been introduced and approved for use in the treatment of multidrug-resistant tuberculosis (MDR-TB). Its mechanism of action is inhibition of adenosine triphosphate-synthase.
Nicholas Gavras, N. W. Schluger
semanticscholar   +1 more source

The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance

bioRxiv
Cavitary tuberculosis (TB) is difficult to cure and a site of relapse. Bedaquiline has been a wonder drug in the treatment of multidrug resistant TB, but emergence of resistance threatens its sustained success.
Annamarie E. Bustion, Jacqueline P. Ernest, Firat Kaya, Connie Silva, Jansy P. Sarathy, L. Blanc, Marjorie Imperial, M. Gengenbacher, Minli Xie, Matthew D. Zimmerman, G. T. Robertson, Danielle M. Weiner, Laura E. Via, Clifton E Barry, R. Savic, Véronique Dartois   +15 more
semanticscholar   +1 more source